SEC Form 4 · accession 0001144204-17-030682
Cellectar Biosciences, Inc. · CLRB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Frederick W Driscoll
Director
Period of report
May 31, 2017
Accepted (ET)
Jun 1, 2017 · 6:04 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001279704
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $1.74 | May 31, 2017 | A | 10,000 | A | — | May 31, 2027 | Common Stock | 10,000 | 10,000 | D |
Explanation of responses
- F1Options vest in equal annual increments over a period of three years from the date of grant.